CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 332 · Search date 2026-07-11 · Methodology v0.6

Lespedeza cuneata extract powder,
does it really help with Improved male climacteric symptoms?

30-Second Summary
C
Evidence Grade C · 48 · Safety acceptable
Eight-week climacteric symptom questionnaires improved, but improvements in hormones, sexual function, and urinary measures were not confirmed
What the
research shows
In an eight-week double-blind RCT of 103 men, Lespedeza cuneata extract powder improved only AMS and ADAM symptom scores, while IIEF, testosterone, and SHBG did not differ from placebo. This was one manufacturer-specific subjective-outcome trial funded by Naturalway with company employees among the authors. A separate 88-person study tested a fenugreek-Lespedeza combination and is not standalone replication, resulting in C.
What the
ads claim
Product descriptions may expand questionnaire improvement into higher testosterone, restored erectile function, improved prostate or urinary function, and general male vitality. These objective and functional outcomes did not improve over placebo in the direct single-ingredient trial.
*

Useful facts when choosing a product

  • The single-ingredient trial product contained 625 mg of extract powder per tablet, taken as two tablets for 1,250 mg/day.
  • The key positive outcomes were the patient-reported AMS and ADAM questionnaires.
  • IIEF, IPSS, testosterone, SHBG, glucose and lipids, and BMI showed no significant between-group differences.
  • Eight-week safety tests did not differ between groups, while long-term and rare-event data remain limited.
Gap Measurement · Verdict 332 · C 48
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2023 study by Kim and colleagues randomized 103 men with AMS scores of at least 37 and testosterone of 500 ng/dL or less to Lespedeza cuneata extract powder at 1,250 mg/day or placebo. At eight weeks, AMS and ADAM improved over placebo, while IIEF, IPSS, testosterone, SHBG, metabolic markers, and BMI showed no significant between-group differences. Naturalway funded the study and two authors were company employees. A 2018 trial by Park and colleagues reported selected positive findings with a 400 mg/day mixed extract of fenugreek seed and Lespedeza, but it cannot isolate the effect of Lespedeza alone.

02

Why this is classified as C (48)

The direct single-ingredient RCT supports an AMS and ADAM signal. It was one Naturalway-funded study with company employees among the authors, IIEF, testosterone, and SHBG were null, and the separate 88-person fenugreek combination is not standalone replication, resulting in C with 48 points.

Counterpoint. A signal for improved patient-reported climacteric symptoms over eight weeks remains in selected middle-aged men. This assessment does not extend that signal to increased hormones or improved sexual or urinary function.

Rejudgment record. Reassessment (cross-check reflected) — In one 103-person eight-week Naturalway-funded trial with company-employee authors, only AMS and ADAM were positive while IIEF, testosterone, and SHBG were null; an 88-person fenugreek-Lespedeza combination trial is not standalone replication

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
AMS and ADAM climacteric symptomsCEight-week symptom scores improved over placebo in one manufacturer-supported RCT.
Testosterone and objective metabolic markersDThe single-ingredient RCT found no between-group differences in testosterone, SHBG, glucose, or lipids.
Sexual function and urinary symptomsDIIEF and IPSS did not improve significantly over placebo.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kim H et al. 2023Single-center randomized double-blind placebo-controlled trial8Funded by Naturalway; two employee authorsAMS, ADAM, IIEF, IPSS, testosterone, SHBG, and metabolic markersAMS and ADAM improved, while IIEF, IPSS, hormones, blood tests, and BMI did not differ between groups.Key
Park HJ et al. 2018Randomized double-blind placebo-controlled mixed-ingredient trial8Ingredient-company linked; company employee authorsAMS, testosterone, ADAM, IIEF, and metabolic markersSelected positive findings were reported for a fenugreek-Lespedeza mixture, but the effect of Lespedeza alone cannot be isolated.Indirect
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-11).

Kim H, Seo YM, Lee S, Kang D, Kim C. 2023. A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Comparative Human Study to Verify the Functionality and Safety of the Lespedeza cuneata G. Don Extract for the Improvement of Aging Male Syndrome. Urol Res Pract. 49(5):316-323. PMID: 37877880. DOI: 10.5152/tud.2023.23065.
checked
Park HJ, Lee KS, Lee EK, Park NC. 2018. Efficacy and Safety of a Mixed Extract of Trigonella foenum-graecum Seed and Lespedeza cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. World J Mens Health. 36(3):230-238. PMID: 29623697. DOI: 10.5534/wjmh.170004.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Lespedeza cuneata extract powder × Improved male climacteric symptoms Evidence Grade C card
[Chamgap] Lespedeza cuneata extract powder × Improved male climacteric symptoms — Evidence Grade C·48. 2 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/mens/lespedeza-cuneata-male-climacteric-symptoms/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.